Differential epitope recognition in the immunodominant staphylococcal antigen A of Staphylococcus aureus by mouse versus human IgG antibodies by Koedijk, D.G.A.M. (Denny) et al.
1SCIentIfIC RepoRts | 7: 8141  | DOI:10.1038/s41598-017-08182-9
www.nature.com/scientificreports
Differential epitope recognition 
in the immunodominant 
staphylococcal antigen A of 
Staphylococcus aureus by mouse 
versus human IgG antibodies
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den Berg2, Jaap Willem Back3, Carolien Kerstholt1, Rianne C. Prins1, Irma A. J. M. Bakker-
Woudenberg2, Jan Maarten van Dijl1 & Girbe Buist1
The immunodominant staphylococcal antigen A (IsaA) is a potential target for active or passive 
immunization against the important human pathogen Staphylococcus aureus. Consistent with this 
view, monoclonal antibodies against IsaA were previously shown to be protective against S. aureus 
infections in mouse models. Further, patients with the genetic blistering disease epidermolysis bullosa 
(EB) displayed high IsaA-specific IgG levels that could potentially be protective. Yet, mice actively 
immunized with IsaA were not protected against S. aureus infection. The present study was aimed at 
explaining these differences in IsaA-specific immune responses. By epitope mapping, we show that the 
protective human monoclonal antibody (humAb) 1D9 recognizes a conserved 62-residue N-terminal 
domain of IsaA. The same region of IsaA is recognized by IgGs in EB patient sera. Further, we show 
by immunofluorescence microscopy that this N-terminal IsaA domain is exposed on the S. aureus cell 
surface. In contrast to the humAb 1D9 and IgGs from EB patients, the non-protective IgGs from mice 
immunized with IsaA were shown to predominantly bind the C-terminal domain of IsaA. Altogether, 
these observations focus attention on the N-terminal region of IsaA as a potential target for future 
immunization against S. aureus.
Staphylococcus aureus can cause a wide variety of diseases and has a strong tendency of developing resistance 
against multiple antibiotics1. Methicillin-Resistant S. aureus (MRSA)- associated infections are becoming increas-
ingly harder to treat. Therefore, a renewed focus on the development of alternative means of treatment has arisen. 
Whereas many infectious diseases are nowadays controlled through vaccination, S. aureus immunity has proven 
hard to achieve with vaccines2–5. As an alternative to the active immunization against S. aureus with vaccines, 
passive immunization with monoclonal antibodies specifically targeting S. aureus is currently explored6–11.
Invariantly expressed cell surface-exposed proteins are attractive potential targets for immunization, due to 
their high accessibility to the human immune system12. This focused attention on the immunodominant S. aureus 
antigen A (IsaA). The IsaA protein was first described in the year 2000 as an antigen recognized by IgGs from 
patients with sepsis caused by MRSA13. Subsequent, proteomic analyses of the S. aureus exoproteome revealed 
that the IsaA protein was invariantly produced by all investigated isolates of this pathogen14, 15. More specifically, 
IsaA is a non-covalently cell wall attached protein that is both exposed to the cell surface and secreted13, 16, 17. The 
IsaA protein has a putative soluble lytic transglycosylase domain at the C-terminus, indicating a role in peptido-
glycan turnover and cell wall hydrolysis17, 18. Interestingly, this C-terminal active site domain is exposed to the 
staphylococcal cell surface while the precise localization of the N-terminal domain was so far not known12, 18. 
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Further, IsaA was localized to the septal region of dividing cells, suggesting its involvement in cell growth, sep-
aration and survival16. In addition to its potential role in cell division, IsaA was shown to be involved in biofilm 
formation17, 19, 20.
The immunodominant nature of IsaA was confirmed by different studies showing that both IgG1 and IgG4 
against this protein are present in sera from a wide range of healthy human individuals and patients13, 21–24. 
Interestingly, healthy S. aureus carriers showed significantly higher IgG levels against IsaA than non-carriers22. 
Furthermore, patients with the genetic blistering disease epidermolysis bullosa (EB), who are highly colo-
nized with S. aureus, displayed very high IgG responses against IsaA23. Notably, EB patients do not frequently 
suffer from S. aureus bacteremia, even though their skin barrier provides only limited protection against 
S. aureus. Although not conclusive, these observations did suggest that the anti-IsaA antibodies and other 
anti-staphylococcal antibodies could perhaps be involved in the protection of EB patients against serious S. aureus 
infections. Furthermore, the high immunogenicity of IsaA and its ubiquitous presence in S. aureus indicated 
that IsaA could be a suitable target for passive immunization. This view was supported by passive immunization 
experiments in animal studies. Firstly, a murine monoclonal antibody (mAb) targeting IsaA was shown to be 
protective in mouse models of catheter-related S. aureus infection7, and a humanized form of this mAb mediated 
bacterial killing in blood samples from high risk patients8. In another study, we showed that a fully human mono-
clonal antibody (humAb) against IsaA (designated 1D9) improved the survival of mice challenged with a clinical 
S. aureus isolate6.
Intriguingly, several active immunization studies in animals also revealed high immune responses against 
IsaA25–28. Nonetheless, no protection against S. aureus infection was observed in these immunized animals. This 
raised the question why certain monoclonal antibodies against IsaA, such as 1D9, are at least partially protective 
against S. aureus infection, while high anti-IsaA IgG levels raised by animal immunization were not protective. 
The present study was aimed at explaining this difference by assessing the IsaA epitopes recognized by the appar-
ently protective and non-protective antibodies. Briefly, the results show that potentially protective antibodies 
recognize a different epitope in IsaA than the non-protective antibodies.
Materials and Methods
Bioinformatics. BLAST searches were performed with default search parameters (Program BLASTP 2.3.0+, 
refs 29 and 30; word size 6; expect value 10; hitlist size 1000; gapcosts 11,1; matrix BLOSUM62; filter string F; 
genetic code 1; window size 40; threshold 21; composition-based stats 2) against the NCBI Protein Reference 
Sequences Database (refseq_protein; posted date: December 7, 2015 10:23 AM). Pfam sequence searches (http://
pfam.xfam.org/search) were performed with default options: use E-value 1.0 cut-off31. Multiple sequence align-
ments were performed using COBALT32 with default parameters (alignment parameters: gap penalties -11, -1; 
end-gap penalties -5, -1; CDD Parameters: Use RPS BLAST on; Blast E-value 0.003; find conserved columns and 
recompute on; query clustering parameters: use query clusters on; word size 4; max cluster distance 0.8; alpha-
bet regular). Visualizations of HMM logos (representing both sequence alignments and profile hidden Markov 
models) were obtained using Skylign (http://skylign.org)33 with the following parameters: alphabet: AA; letter 
height: information content above background; alignment processing: HMM - remove mostly-empty columns. 
Predicted protein masses (kDa) and isoelectric points (pI) were obtained using the Expasy compute pI/Mw tool 
(web.expasy.org/compute_pi/). Data from Western blots were quantified by ImageJ software (available via http://
rsbweb.nih.gov/ij/).
Bacterial strains and growth conditions. Bacterial strains and plasmids that were used in this study 
are listed in Table 1. Staphylococcal strains were grown at 37 °C, 250 rpm (0.87 × g) in Tryptone Soy Broth (TSB; 
Oxoid, Hampshire, UK). L. lactis strains were grown at 30 °C in M17 broth (Oxoid Limited) or on M17 plates 
with 1.5% agar and 0.5% glucose (w/v), supplemented with chloramphenicol (5 µg/ml) for plasmid selection. For 
in vivo studies the S. aureus clinical isolate P15 was grown in Brain Heart Infusion broth (BHI; Becton Dickinson, 
Breda, The Netherlands).
Construction of expression plasmids for the production of IsaA and its derivatives. PCR primers 
for the construction of IsaA protein-expressing plasmids are shown in Supplementary Table 1. DNA was isolated 
with the Genelute bacterial genomic DNA kit (Sigma-Aldrich, Zwijndrecht, The Netherlands). PCR was per-
formed with the Phusion Hot Start II polymerase (Thermo Fisher Scientific, Wilmington, Delaware USA) using 
genomic DNA of S. aureus NCTC8325 as a template as described before34. The PCR fragments purified using 
the High Pure PCR purification kit (Analytic Jena, Jena, Germany) were cleft with BamHI and NotI restriction 
enzymes (New England Biolabs, Ipswich, USA) and ligated to BamHI/NotI-linearized vector DNA using T4 
DNA Ligase (New England Biolabs). Of note, PCR products obtained with primer combinations including a 
reverse primer with a stop codon (F1/R2) were inserted into plasmids pNG4110, and PCR products obtained with 
reverse primers lacking a stop codon (F1/R1) were inserted into plasmid pNG4210. The resulting plasmids were 
transferred to electrocompetent L. lactis PA1001 as described before35. All plasmids were verified by sequencing 
(Eurofins MWG Operon, Ebersberg, Germany).
HumAb production and labeling. The humAb 1D9 directed against S. aureus IsaA was produced as 
described before6. Briefly, Expi293 cells were transiently transfected with plasmids encoding the H and K frag-
ments of 1D9 (Expi293 Expression System, Life Technologies). Secreted 1D9 antibodies were isolated from the 
cell culture medium by Protein A column purification (HiTrap Protein A HP, GE Lifesciences) followed by desalt-
ing (HiTrap Desalting, GE Lifesciences) according to the manufacturer’s protocol. 1D9 F(ab’)2 nanobodies were 
derived from the complete 1D9 humAb using the FragIT kit (Genovis, Sweden) following the manufacturer’s 
protocol. The complete 1D9 antibody or the respective 1D9 F(ab’)2 nanobodies were labeled with IRDye 800CW 
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(LI-COR Biosciences, Bad Homburg, Germany) by incubation with 20 µg of this dye per mg of protein in PBS 
(pH 8.5, 2 h, room temperature). The labeled antibodies were isolated and desalted as described above, and they 
were stored in the dark at 4 °C.
Protein expression, purification and detection of IsaA and its subdomains. The production 
and isolation of IsaA-His6 from E. coli BL21DE3 (pET24d::isaA::his6) was performed as described previously6. 
Expression of IsaA and its derivatives in L. lactis PA1001 was induced with nisin (3 ng/ml, Sigma-Aldrich, St. 
Luis, MO) at an Optical Density at 600 nm (OD600) of ~0.5. After continued overnight incubation at 30 °C, cells 
were separated from the growth medium by centrifugation. Protein samples from both fractions were prepared 
as described before34. All proteins obtained were analyzed by Lithium Dodecyl Sulphate (LDS)-PAGE (NuPAGE 
gels, Life Technologies), and visualized either by protein staining (Simply BlueTM Safe Staining, Life Technologies) 
or by Western blotting on nitrocellulose membranes (Protan nitrocellulose transfer paper, Whatman, Germany). 
Immunodetection of particular proteins was achieved with the following antibodies or sera: mouse anti-His tag 
(Life Technologies), rabbit anti-IsaA (kindly provided by N. Sakata)16, sera from mice immunized with IsaA, rab-
bit anti-SceD (kindly provided by S. Foster)17 or the IRDye 800 CW-labeled 1D9 anti-IsaA humAb6. The binding 
of unlabeled antibodies was visualized with fluorescently labeled goat anti-human, goat anti-mouse or donkey 
anti-rabbit IRDye 800 CW-labeled secondary antibodies (LI-COR Biosciences, Lincoln, NE. USA), using the 
Odyssey Infrared Imaging System (LI-COR Biosciences).
Cell wall extraction and binding experiments. Crude cell wall extracts were obtained from overnight 
cultures of S. aureus MA12 ΔisaA or S. aureus Newman ΔspaΔsbi. To this end, cell pellets were resuspended in 
demineralized water with 0.1 µm glass beads (Biospec Products, Bartlesville, USA) and disrupted in a Precellys 
24 homogenizer (Bertin Technologies, France), followed by centrifugation at 4000 rpm (1520 × g) for 6 min. 
Recovered supernatants were centrifuged for 15 min at 14000 rpm (18620 x g) and pellets containing crude cell 
wall extracts were resuspended in demineralized water and stored at 4 °C. Non-covalently bound cell wall pro-
teins were extracted from S. aureus Newman ΔspaΔsbi cells by a 10 min incubation with 1 M potassium thiocy-
anate (KSCN) as described previously36.
Strain or plasmid Relevant phenotype(s) or genotype(s) Source or reference
Strains
L. lactis PA1001 MG1363 pepN::nisRK allows nisin-inducible expression, ΔacmA ΔhtrA 46
S. aureus NCTC8325-4 NCTC8325 cured of φ11, φ12, and φ13 47
S. aureus isolate P Community-acquired MSSA strain from blood of a septic patient 15
S. aureus MA12 ΔisaA S. aureus MA12 isaA mutant 7
E. coli BL21DE3 Allows IPTG-inducible expression of PT7 Novagen
S. aureus Newman ΔspaΔsbi spa sbi mutant 36
S. aureus isolates D, E, F, G, H Community- and hospital acquired clinical isolates collected in the University Medical Center Groningen over a 4.5-year period 15
Plasmids
pET24d::isaA::his6 KanR, pET24d containing isaA with C-terminal his6 34
pNG4110 Cm
R, pNG400, containing PnisA, SSusp45, his6, BamHI/EcoRI-
XbaI/NotI cloning sites 48
pNG4210 pNG400 containing BamHI/EcoRI-XbaI/NotI cloning sites, his6 48
pNG4110::isaA pNG4110 encoding residues 30–233
a from S. aureus NCTC8325 
IsaA This study
pNG4110::isaA-N pNG4110 encoding residues 30–145 from IsaA This study
pNG4110::isaA-N1 pNG4110 encoding residues 30–91 from IsaA This study
pNG4110::isaA-N2 pNG4110 encoding residues 92–145 from IsaA This study
pNG4110::isaA-C pNG4110 encoding residues 146–233 from IsaA This study
pNG4110::isaA-C1 pNG4110 encoding residues 146–189 from IsaA This study
pNG4110::isaA-C2 pNG4110 encoding residues 190–233 from IsaA This study
pNG4210::isaA pNG4210 encoding residues 30–233 from IsaA This study
pNG4210::isaA-N pNG4210 encoding residues 30–145 from IsaA This study
pNG4210::isaA-N1 pNG4210 encoding residues 30–91 from IsaA This study
pNG4210::isaA-N2 pNG4210 encoding residues 92–145 from IsaA This study
pNG4210::isaA-C pNG4210 encoding residues 146–233 from IsaA This study
pNG4210::isaA-C1 pNG4210 encoding residues 146–189 from IsaA This study
pNG4210::isaA-C2 pNG4210 encoding residues 190–233 from IsaA This study
Table 1. Bacterial strains and plasmids used in this study. KanR, kanamycin resistance gene; CmR, 
chloramphenicol resistance gene; PT7, IPTG inducible T7-promoter; PnisA, nisin inducible promoter; his6, 6 
histidine-tag; SSusp45, signal sequence of usp45; aposition of amino acid residues (aa) in IsaA sequence of S. aureus 
NCTC8325 (YP_501340).
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Growth medium fractions of overnight nisin-induced cultures expressing IsaA protein fragments were precip-
itated with 10% TCA. The resulting protein pellets were resuspended in 4-fold diluted phosphate buffered saline 
with 0.1% Tween 20 (PBS-T), and proteins were analyzed by LDS-PAGE. For rebinding experiments, crude cell 
wall extracts were incubated with IsaA protein fragments (obtained as described above) at room temperature 
for 10 min and, thereafter, the binding of the IsaA fragments was assessed by LDS-PAGE and Western blotting.
Near Infrared Microscopy. Aliquots of 1 ml of bacterial cultures (OD600 of 1) in TSB were collected, washed 
twice with PBS, and resuspended in 1 ml of PBS. Next, ~1010 cells thus obtained were incubated with 0.65 mg/ml 
IRDye 800CW-labeled 1D9 or 1D9 F(ab’)2 for 1 h at room temperature. After washing 3 times with PBS, cells were 
spotted on poly-L-lysine-coated glass slides (Sigma Aldrich) and inspected using a Leica DM5500B epifluores-
cence microscope equipped with an 800 nm filter block. Images were captured with a Leica DFC365FX camera 
using a 63× objective (Leica Microsystems BV, The Netherlands).
Epitope mapping with peptide arrays. To determine which epitopes of S. aureus IsaA were recognized 
by the investigated anti-IsaA IgGs, libraries of linear 15-mer IsaA-specific peptides were synthesized with an 
overlap on a solid support (Pepscan), as previously described37, 38. Next, the peptide libraries were probed with 
heat-inactivated mouse sera, humAb 1D9, or rabbit anti-IsaA in a dilution of 1:1000. Bound IsaA-specific anti-
bodies were detected with a secondary HRP-conjugated antibody (Southern Biotech, Birmingham, USA) and 
2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (Sigma-Aldrich). A charge-coupled device camera was 
used to record the absorbance at 405 nm.
Immunization of mice with IsaA. Specified pathogen-free female BALB/cBYJ mice were obtained from 
Charles River (Saint-Germain-sur-l’Arbresle, France). Mice were treated and selected as described previously27. 
Purified IsaA-His6 was emulsified 1:1 with TiterMax Gold adjuvant (Sigma-Aldrich). Mice were immunized sub-
cutaneously in the flank with 100 μL formulated vaccine on days -28, -21, and -14 (25 μg of antigen). Control mice 
received 100 μL PBS emulsified with adjuvant. At day -1, blood was withdrawn from the tail artery. Sera were 
examined by ELISA using ELISA plates (Greiner Bio-One B.V, Alphen aan den Rijn, the Netherlands), coating, 
blocking, hybridization and detection procedures as described previously27. Immunized mice (n = 6 immunized 
mice, n = 11 placebo-immunized mice) were challenged on day 0 by intravenous inoculation of 100 μL of S. 
aureus isolate P (3 × 105 CFU) as described previously27. Discomfort and animal survival rate over 14 days after 
infection were monitored. For discomfort score, clinical signs of illness in each mouse were evaluated at least 
twice daily as described before27.
Ethics statements. Blood donations from EB patients were collected under the approval of the medical 
ethics committee of the University Medical Center Groningen (approval no. NL27471,042,09) upon written 
informed patient consent, and with adherence to the Helsinki Guidelines23. The required written informed con-
sent was obtained from all EB patients and healthy volunteers included in the present studies. The Institutional 
Animal Care and Use Committee of the Erasmus University Medical Centre Rotterdam approved the present pro-
tocols for animal experiments (permit number: EMC2694). All animal experiments were performed in accord-
ance with the rules laid down in the Dutch Animal Experimentation Act and the Directive 2010/63/EU on the 
protection of animals used for scientific purposes.
Results
IsaA contains 2 conserved domains. As a first approach towards the identification of antigenic epitopes 
in IsaA, we performed a bioinformatics analysis of the domain structure of this protein. Inspection of the amino 
acid sequence of IsaA using Pfam only showed the presence of the known soluble lytic transglycosylase domain 
(SLT, pfam01464) in the C-terminus (Fig. 1B). Subsequent BLASTP searches against the NCBI Protein Reference 
Sequences Database using the N-terminus of IsaA (residues 30–145) revealed another conserved domain ranging 
from residues 30 to 84. A following Position-Specific iterated BLAST search with this region of IsaA showed that 
this domain is exclusively present in the N-termini of 391 proteins, primarily the IsaA and SceD proteins from 
S. aureus and other staphylococcal species (Fig. 1A and Supplemental Fig. 1). In what follows, we refer to this 
N-terminal Conserved Domain as the NCD domain of IsaA.
IsaA is non-covalently bound to the staphylococcal cell wall. To investigate the subcellular locali-
zation of IsaA, several experiments were performed. Fractionation and subsequent Western blotting analyses of 
S. aureus MA12, MA12ΔisaA and Newman ΔspaΔsbi showed that IsaA is both retained in the cell fraction and 
released into the culture medium (Fig. 2A). Furthermore, extraction of non-covalently cell wall-bound proteins 
from S. aureus Newman ΔspaΔsbi cells with KSCN resulted in the release of IsaA from the cells (Fig. 2A, lane 
labelled W). As KSCN is a chaotrope, the release of IsaA from the cells implies that this protein is associated 
with the cell wall through non-covalent cell wall interactions based on hydrogen bonds, van der Waals forces, 
or hydrophobic interactions (Fig. 2A). In contrast to IsaA, the IsaA paralogue SceD is mostly secreted into the 
growth medium by clinical S. aureus isolates that produce this protein (Fig. 2B). Of note, the full size 1D9–800CW 
antibody also binds to the IgG binding proteins Spa (protein A) and Sbi whereas, as expected, 1D9 F(ab’)2-800CW 
nanobodies do not bind to these proteins since they lack the Fc moiety needed for Spa- and Sbi-binding (Fig. 2A). 
Consistent with the Western blotting data, fluorescence microscopy showed that 1D9 F(ab)2-800CW binds to 
whole cells of the wild-type S. aureus MA12 strain, but not to cells of S. aureus MA12 ΔisaA (Fig. 3).
To further investigate the potential of IsaA for cell wall binding, the mature protein and its N- and C-terminal 
fragments were expressed in L. lactis using vectors pNG4110 and pNG4210 as schematically represented in 
Fig. 1B. Specifically, this resulted in the nisin-inducible production of: the N-terminal conserved domain (N; 
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residues 30–145), the N-terminal sub-domains N1 (residues 30–91) and N2 (residues 92–145), the C-terminal 
domain with the SLT active site domain, (C; residues 146–233), and the C-terminal fragments C1 (residues 146–
189) and C2 (residues 190–233). These fragments were expressed either with a C-terminal His-tag or with an 
N-terminal His-tag. Further, all His-tagged fragments were attached to an N-terminal signal peptide, allowing 
their facile purification from the growth medium of L. lactis (Fig. 1C, simply blue staining panel and Western 
blot panel with α-His-tag antibodies). Of note, for unknown reasons the N and N2 fragments of IsaA had a 
lower mobility on the denaturing LDS-PAGE gels than expected based on their molecular weight. Analysis of the 
whole-cell and growth medium fractions of the L. lactis cultures expressing the different fragments or the full-size 
IsaA protein showed that mature IsaA and the N, N1 and C fragments can be detected both in the cells and the 
growth medium (Fig. 4A). The localization of these fragments was not affected by the presence of the His-tag at 
the N- or C-termini. In case of the N1 fragments most of the protein was present in the cells, suggesting that this 
IsaA moiety is of particular relevance for cell association. Conversely, relatively low amounts of the C fragment 
were localized to the cell fraction. Importantly, the N2, C1 and C2 fragments were exclusively detected in the 
growth medium fraction, suggesting that they have no important role in cell association (Fig. 4A).
Figure 1. Schematic representation of IsaA subdomains, their separate expression and immunodetection. (A) 
The N-terminal conserved domain (NCD) of IsaA (residues 30–84) as identified by BLASTP searches with the 
N-terminal region of IsaA (residues 30–145; see also Supplementary Fig. 1). (B) The mature IsaA, its N-terminal 
(IsaA-N, IsaA-N1, IsaA-N2) or C-terminal (IsaA-C, IsaA-C1, IsaA-C2) fragments were expressed in L. lactis 
PA1001 and secreted as N-terminal or C-terminal His-tag fusions using the lactococcal signal peptide of Usp45 
(spu). The C-terminal part of IsaA contains a soluble lytic transglycosylase (SLT) domain (pfam01464). In 
the schematic representations of the expression vectors pNG4110 and pNG4210, used to produce IsaA or its 
subdomains, the positions of the cleavage sites for the restriction enzymes BamHI (B) and NotI (N), and the 
N-terminal or C-terminal His-tags (h6) are indicated. Molecular weights (kDa) of IsaA and its subdomains and 
their isoelectric points (pI) are indicated. sp, IsaA signal peptide; *Stop codon provided within the expression 
vectors pNG4110 and pNG4210. (C) LDS-PAGE analysis of growth medium fractions of nisin-induced L. 
lactis cultures producing the C-terminally His-tagged IsaA protein or IsaA fragments. The His-tagged proteins 
are visualized either by Simply Blue gel-staining, or by Western blotting with the humAb 1D9–800CW, the 
polyclonal α-IsaA rabbit antibodies, or α-His-tag antibodies. Molecular weights (kDa) of the standard proteins 
are indicated on the left.
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As the above cell association analysis was performed with the heterologous organism L. lactis, a cell wall 
rebinding analysis was performed using crude cell wall preparations of S. aureus MA12 ΔisaA to verify the cell 
wall binding capabilities of IsaA. This approach is based on the notion that non-covalently cell wall-bound pro-
teins that have been released into the growth medium can in principle rebind to the S. aureus cell wall. In these 
experiments, we focused on S. aureus cell wall rebinding of the full-size IsaA, or the N or C fragments of IsaA, as 
purified from the growth medium of L. lactis. Upon incubation with the cell wall preparations, the cell walls were 
pelleted and the presence of IsaA (fragments) in the pellet and supernatant fractions was assessed by Western 
blotting. As shown in Fig. 4B, the full-size IsaA and the N fragment were capable of rebinding to the S. aureus 
cell wall, albeit that rebinding of the N fragment was less effective depending on the position of the His-tag. In 
contrast, the C fragment of IsaA did not rebind to the S. aureus cell wall. For control, the assay was performed also 
in the absence of cell wall extract. As presented in Fig. 4C, Simply Blue gel staining showed that hardly any IsaA 
was pelleted in the absence of cell wall extract, although a relatively small amount of pelleted IsaA was detectable 
by Western blotting. The latter probably represents a small amount of aggregated IsaA or IsaA bound to the tube. 
Altogether, the present observations show that IsaA has a modular structure composed of a conserved N-terminal 
domain and an active site domain in the C-terminus. Both domains are involved in effective binding of full-size 
IsaA to the S. aureus cell wall, albeit that the N-terminal domain can also bind to the cell wall in absence of the 
C-terminal domain.
HumAb 1D9 binds to the NCD domain of IsaA. The potentially different functions of the N and C 
domains of IsaA in cell wall binding and transglycosylase activity raised the question, which epitope(s) in IsaA 
need(s) to be recognized for a protective antibody response? As a first approach to answer this question, we 
assessed the binding site of our humAb 1D9 in IsaA using the different fragments of this protein expressed in 
L. lactis. As demonstrated by Western blotting, humAb 1D9 labeled with IRDye800CW binds effectively to the 
IsaA fragments N and N1, but not to the fragments N2, C, C1 and C2 (Fig. 1C). This shows that the epitope rec-
ognized by 1D9 resides within the first 62 residues of the mature IsaA protein. By contrast, all tested fragments 
of IsaA were bound by the polyclonal antibodies (α-IsaA) raised in a rabbit16 (Fig. 1C). To further narrow down 
the epitope recognized by 1D9, we applied the PepScan technology37, 38, where antibody binding to an array with 
linear 15-mer peptides representing the entire IsaA protein was tested. Unexpectedly, 1D9 did not bind to this 
array (not shown), while the polyclonal rabbit α-IsaA antibodies did bind to the array (Fig. 5). In fact, the profile 
Figure 2. Cell-associated and secreted forms of IsaA and SceD. (A) S. aureus MA12, S. aureus MA12 ΔisaA 
and S. aureus Newman ΔspaΔsbi were grown overnight. Subsequently, cells (C) were separated from the 
growth medium (M) by centrifugation and proteins in the respective fractions were separated by LDS-PAGE. 
In addition, non-covalently cell wall-associated proteins (W) were extracted from S. aureus Newman ΔspaΔsbi 
and separated by LDS-PAGE. The presence of IsaA was subsequently visualized by Western blotting using 
humAb 1D9-800CW, hum Ab 1D9 F(ab)2-800CW or the polyclonal rabbit antibody α-IsaA. Molecular weights 
(kDa) of marker proteins are shown on the left and the positions of Protein A, Sbi and IsaA are indicated on 
the right. (B) Cellular (C) and secreted proteins in the growth medium (M) of the clinical S. aureus isolates 
(D,E,F,G and H) were separated by LDS-PAGE and detected by Western blotting using an α-SceD polyclonal 
antibody. Molecular weights (kDa) of marker proteins are shown on the left and the positions of protein A and 
SceD are indicated on the right.
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of polyclonal α-IsaA binding to the peptide array mirrored the results obtained by Western blotting, where the 
N, N1, N2, C, C1 and C2 fragments of IsaA were all shown to bind the polyclonal antibodies (Fig. 1C). Taken 
together, these findings show that humAb 1D9 binds to an epitope within the conserved NCD domain of IsaA, 
and that this epitope is not represented in the array of linear 15-mer peptides. The latter finding suggests that 1D9 
binding to IsaA relates to a feature with a particular secondary or tertiary structure.
Distinction of IsaA epitopes recognized by human sera and sera from IsaA-immunized 
mice. Our previous mouse immunization study with an octavalent anti-S. aureus vaccine including IsaA 
showed that antibodies against IsaA were not protective27. This previous conclusion was verified by immunizing 
mice with IsaA only, which showed that high IsaA-specific IgG titers did not protect mice against a challenge with 
the methicillin-sensitive S. aureus (MSSA) isolate P (Supplementary Figs 2 and 3). To determine whether the 
IsaA epitopes recognized by potentially protective IsaA-specific IgGs from six EB patients, and six non-protective 
IsaA-specific IgGs from immunized mice are similar or different, we employed a Western blotting approach. The 
results in Fig. 6 show that all tested sera of mice and men contained IgGs recognizing the full-size IsaA and the 
IsaA fragment N. All sera from mice contained IgGs recognizing fragment C, whereas this was significantly less 
common for the sera from EB patients. None of the tested sera contained IgGs recognizing fragment C2, and only 
two of the tested mouse sera contained IgGs recognizing fragment C1. Intriguingly, a distinguishing feature of 
the EB patient sera was that, with exception of the EB patient serum 51, all contained significant levels of IgGs 
against the N1 fragment (between ~22 to 41% of the total signal). Overall, this suggests that the IsaA-specific IgGs 
of EB patients preferentially recognize the N1 fragment of IsaA, similar to the protective humAb 1D9, whereas 
the non-protective IsaA-specific IgGs of immunized mice preferentially recognize the C fragment of IsaA (Fig. 6).
Discussion
The aim of this study was to localize immunogenic epitopes in the IsaA protein of S. aureus and to correlate the 
recognition of these epitopes by particular IgGs to protection against S. aureus infection. The results show that 
IsaA-specific human IgGs predominantly target a conserved N-terminal domain in IsaA, while IsaA-specific 
murine IgGs predominantly target the conserved C-terminal domain of IsaA.
Previous studies have shown that the C-terminal part of IsaA contains a soluble lytic transglycosylase (SLT) 
domain (Pfam 06737) that is conserved also in the SceD protein of S. aureus. This SLT domain is able to cleave 
peptidoglycan, and impacts on the clumping and separation of S. aureus cells17. In contrast, a possible function of 
the N-terminal region of IsaA was so far not known. Of note, our present data show that this N-terminal region 
contains a domain (NCD) that is well conserved in the IsaA and SceD proteins of a wide range of Staphylococcus 
species. Using proteomics approaches, it was previously shown that IsaA and SceD both are non-covalently cell 
wall-bound proteins18, 39–41. As it is known that most peptidoglycan hydrolases are composed of a catalytic site 
Figure 3. Exposure of IsaA on the S. aureus cell surface. Phase contrast (left panels) and near-infrared 
fluorescence (right panels) microscopic images of overnight cultured S. aureus cells treated with 1D9 F(ab)2-
800 CW. Top panels, S. aureus MA12 ΔisaA cells; bottom panels wild-type (wt) S. aureus MA12 cells.
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domain and a cell wall binding domain42, we hypothesized that the NCD domain could contribute to cell wall 
binding. Indeed, separate expression of the different regions of IsaA showed that the N-region, which includes 
the NCD domain, has affinity for cell walls of S. aureus and L. lactis. In contrast, the C-terminal region does 
apparently not bind cell walls by itself. Yet, the highest levels of cell wall binding were observed for the intact IsaA 
protein, indicating that both the N- and C-regions are involved in cell wall binding with a potentially more prom-
inent contribution from the N-region. It should be noted, however, that a substantial portion of IsaA is secreted 
into the growth medium, and this is also the case for SceD. Consistent with the observed cell wall binding of IsaA, 
Figure 4. Cell wall association of IsaA-derived protein fragments. (A) IsaA, its N-terminal (IsaA-N, IsaA-N1, 
IsaA-N2) and C-terminal (IsaA-C, IsaA-C1, IsaA-C2) fragments were expressed in L. lactis PA1001 with the 
Usp45 signal peptide for export from the cytoplasm and an N-terminal (←) or C-terminal (→) His-tag (see 
Fig. 1B). Next, cells (C) were separated from the growth medium (M) by centrifugation and the presence of full-
size IsaA or its fragments in the respective fractions was analyzed by Western blotting using α-IsaA polyclonal 
rabbit antibodies. (B) The rebinding potential of secreted IsaA or IsaA-derived fragments to the S. aureus 
cell wall was assessed using full-size IsaA or IsaA-derived fragments (as described in A) and crude cell wall 
extracts from S. aureus MA12 ΔisaA as described in the Materials and Methods section. Upon incubation for 
10 min, the cell walls were pelleted by centrifugation and proteins in the pelleted cell wall (W) and supernatant 
(S) fractions were analyzed by LDS-PAGE and Simply blue staining (upper panels) or Western blotting using 
α-IsaA polyclonal rabbit antibodies (lower panels). (C) As a control, IsaA was incubated without the crude cell 
wall extract from S. aureus MA12 ΔisaA and upon incubation centrifuged. Pellet and supernatant fractions 
were processed as described in (B). The molecular weights (kDa) of marker proteins are indicated on the left.
Figure 5. Antibody reactivity against IsaA epitopes measured by pepscan-ELISA. Bar chart with relative 
fluorescence signals as detected upon binding of α-IsaA polyclonal rabbit antibodies to 15-mer peptides with 
14 residue overlap. The peptides are ordered on the x-axis according to the position of their N-terminal residue 
in the overall IsaA amino acid sequence. The relative positions of the IsaA fragments N1, N2, C1 and C2 are 
indicated. The y-axis shows the OD (in AU).
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we did observe localization of this protein to the S. aureus cell surface using an immunofluorescence microscopy 
approach. Of note, this involved an IRDye 800CW-labeled F(ab)2 fragment of the humAb 1D9, which binds to the 
N1 subdomain of IsaA. Together, these observations imply that the N-domain of IsaA is exposed on the S. aureus 
cell surface, where it is accessible to IgG.
Intriguingly, our present results show that sera of patients with the genetic blistering disease EB contain IgGs 
that predominantly target the N-domain of IsaA. Chronic wounds of these patients are heavily colonized with S. 
aureus43, 44, which was previously shown to elicit IgG levels against S. aureus proteins that were much higher than 
the IgG levels against the respective proteins in healthy volunteers23. The highest IgG levels were detected against 
the IsaA protein, leading to the view that these IgGs could be protective against S. aureus infections23. This view is 
supported by the fact that EB patients rarely suffer from invasive S. aureus infections despite the high-level colo-
nization of their wounds45, and by the observation that monoclonal antibodies against IsaA (i.e. 1D9 and UK-66) 
can be protective against S. aureus infection in mouse models6–8. Of note, our present study also shows that that 
the protective humAb 1D9 also recognizes the N-domain of IsaA. In contrast to our findings with the sera of EB 
patients, the immunization of mice with purified IsaA did not elicit the production of IgGs that protect against S. 
aureus infection. In this case, the IsaA-specific IgGs predominantly recognized the C-terminal region of IsaA as 
shown in our present study. Together, these observations imply that IgGs against the C-terminal region of IsaA do 
not effectively protect against S. aureus infection. On the other hand, it is presently not possible to conclude that 
the high titers of anti-IsaA antibodies in EB patients, which bind to the N-terminal domain of IsaA, are indeed 
protective. For example, antibodies against other S. aureus components that are also present at high levels could 
contribute to the protection of EB patients against S. aureus bacteremia. In addition, it is also conceivable that 
differences in cell-medicated immunity contribute to the apparent protection of EB patients against S. aureus.
A key question that remains to be answered is why does there appear to be a bias towards IgGs specific for 
the N-terminal region of IsaA in EB patient sera, and a bias towards IgGs specific for the C-terminal region in 
immunized mice? Our present studies show that the N-terminal region of IsaA is exposed on the cell surface of S. 
aureus, which might suggest that this domain is better exposed to the human immune system than the C-terminal 
region of IsaA. Yet, our previous proteomics study, where S. aureus cells were shaved with trypsin that was immo-
bilized on agarose beads, clearly showed that also the C-terminus of IsaA is exposed to the S. aureus cell surface12, 
18. This makes a differential exposure of the N- and C-terminal regions of IsaA on the S. aureus cell surface a less 
likely explanation for the observed differences in the IgG specificities from mice and men. An alternative expla-
nation could be that the immunogenicity of the N- and C-terminal domains of IsaA is different, depending on 
whether the immune system is challenged with IsaA attached to the S. aureus cell surface or with soluble IsaA. 
Conceivably, such a difference could relate to conformational differences in the respective domains when they are 
associated with the cell or secreted into the growth medium.
Conclusion
Altogether, our present study shows that the immune responses to IsaA are very different in the investigated 
mouse and human sera. In particular, the results seem to suggest that IgGs against the N-terminal domain of IsaA 
are potentially protective against S. aureus infection. This focuses attention on the N-terminal region of IsaA as a 
potential component in a future vaccine against the important human pathogen S. aureus. To validate this idea, 
protection studies need to be performed in an appropriate animal model, where the separated N- and C-terminal 
fragments of IsaA are used for active immunization.
Figure 6. Differential binding of human and murine IgGs to IsaA-derived fragments. Proteins in the growth 
medium fractions of L. lactis PA1001 producing the full-size IsaA or N-terminal (N, N1, N2) or C-terminal 
(C, C1, C2) fragments of IsaA were separated by LDS-PAGE. Next, a Western blotting analysis was performed 
using sera from EB patients (EB01, EB09, EB11, EB15, EB51 and EB55) or sera from the mice immunized with 
IsaA (M31, M32, M33, M34, M35 and M36). The molecular weights (kDa) of marker proteins are indicated 
on the left. The intensities of detected bands were assessed with ImageJ, and the relative intensity for each 
band is indicated below each blot as the percentage of the total intensity determined for full-size IsaA plus the 
N-terminal (N, N1, N2) and C-terminal (C, C1, C2) fragments.
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